Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2026 | Approaching secondary prevention in patients with breakthrough stroke

Ronda Lun, MD, MSc, FRCPC, University of Calgary, Calgary, Canada, discusses her approach to secondary stroke prevention in patients who meet AF-BREACH criteria, emphasizing the importance of vascular risk factor control. Dr Lun highlights the need to address modifiable risk factors and considers referring patients to trials like the LAAOS-4 trial (NCT05963698), which investigates left atrial appendage occlusion plus direct oral anticoagulant (DOAC) versus DOAC alone. This interview took place at the 18th World Stroke Congress (WSC) in Seoul, Korea.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Just as with secondary prevention in any ischemic stroke, I think looking at vascular risk factor control is really important. So regardless of the underlying etiology of their breakthrough stroke, you know, addressing things like blood pressure control, lipids, diabetes management, smoking cessation, these are all the kind of low-hanging fruit, let’s call it. And then next, I think, you know, we really have a lot to learn still about the management of breakthrough strokes in AF...

Just as with secondary prevention in any ischemic stroke, I think looking at vascular risk factor control is really important. So regardless of the underlying etiology of their breakthrough stroke, you know, addressing things like blood pressure control, lipids, diabetes management, smoking cessation, these are all the kind of low-hanging fruit, let’s call it. And then next, I think, you know, we really have a lot to learn still about the management of breakthrough strokes in AF. And so what I try to do is actually enroll these patients in clinical trials if it’s possible. So in these patients who do meet AF-BREACH criteria, I try to refer them to the LAAOS-4 trial is currently going on at my institution, which randomizes patients to left atrial appendage occlusion plus DOAC versus DOAC alone. And so I think it’s really important to use this as an opportunity to try to help answer the question for future patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.